Immupharma Share Discussion Threads

[hamhamham1] 10/1/2018 06:56

Your second sentence:
"I’d be a buyer at £1.25"
I guess maybe explains the first sentence:
"I expect the MMs to drop this again today to scare holders out. Once £1.50 is breached I think it could fall away quite quickly triggering stop losses and fear will creep in."
Glad you being honest about your thoughts, I am holding so no plans to do anything until actual news comes out rather than getting washed around in the current.

[ytsa2] 10/1/2018 06:27

It was frothy last week if anything reaching a high of 190 or so. Down to around 160 on Monday?

[perfect pete] 10/1/2018 06:27

Well you called 1.50 almost on the nose, fair play!

[john09] 10/1/2018 04:38

I expect the MMs to drop this again today to scare holders out. Once £1.50 is breached I think it could fall away quite quickly triggering stop losses and fear will creep in. I’d be a buyer at £1.25 in terms of a risk reward punt but as I said boy was it inflated and frothy on Monday

[ny boy] 10/1/2018 03:41

perfect pete9 Jan '18 - 18:16 - 9192 of 9212

Ny boy would you mind if i asked what you call your day job?

I invest in start ups & under-valued Companies, I started buying these 52p

[l0ngterm] 10/1/2018 00:25

Njb: I think the length of the analysis will depend on the below key points. But if there is a clear difference between the placebo group and lupuzor then I imagine a market update could be released. Not sure how the fda would view that?From further reading the fda logs and capture adverse events under various categories.Adverse events: none serious so farDrop outs: figure unknown, reasons to be supplied. Statistics: could be calculated automatically and charted using software.Then just wording around this.

[njb67] 09/1/2018 23:58

Thanks Long

He is describing the ongoing capture and QC of data, which is how all trials work. What we need to bottom out is how quickly after data lock (lets assume 10 days post last data point being recorded) can we expect headline results. I was told a few months, but will go back and double check. I have emailed someone this evening to clarify.

It is also a question we should put to IMM and/or its advisors.

[l0ngterm] 09/1/2018 23:47

From an interview with directors talk.

[l0ngterm] 09/1/2018 23:46

See a&a with Tim below, data being collected as the trial goes along.Q1 2018? A5: I think we're very confident and the trial is going absolutely according to plan. In terms of announcing any results in the study, it's not only just about completely the patients through the study themselves but it's about collecting all the data and analysing it and then putting that into some sort of format which we can then deliver what the results are. So, we're working very closely with our Clinical Research Organisation (CRO), Simbec-Orion, on this and what they are doing is collecting the data from patients as we go along because it does take a little while to process all the information and data which is collected from patients during the study. So, if we were to wait until the end of the study, in other words when the last patient had completed, to process all the data it would take Simbec-Orion a long time. So, that data is being processed as we go along so when the last patient completes their 12 months then we'll only have small amount of data to complete and so we know exactly when the last patient is completing the 12 months. Looking at that and giving a little bit of time to complete the analysis of the data we're absolutely confident we'll get these results out in the first quarter next year. http://www.immupharma.co.uk/wp-content/uploads/2017/10/DirectorsTalk-Highlights-sept-20171.pdf

[stealth wealth] 09/1/2018 23:24

Someone previously said Simbac Orion have software into which all data is fed and it could be updated remotely from any Centre, speeding up time for release of headline results and full analysis.someone also said the US and EU trials ended some time ago so that data is ready for unblinding next week, with just the last of the Mauritius data to be updated.

[che7win] 09/1/2018 22:43

Thanks Spawny

[njb67] 09/1/2018 22:29

Long.
The size of the trial apparently has little effect on the time it takes to undertake the analyses and create reports. The analyses are pre-programmed and the reports cover many of the same analyses.

Bermuda
I had understood from my conversation that the results were released only after the report was produced, I will check though as it is possible that the question I asked was not sufficiently precise.

[bermudashorts] 09/1/2018 21:10

njb67 - they don't need to complete the CTR before they announce headline results but agree late Feb to March is most likely.

happyman - not sure what Sylviane Muller's appearance has to do with anything

[wi1l] 09/1/2018 20:59

Lets hope so. A couple of months with the share price yo-yoing up and down will not be good for my constitution! I was convinced that it would go up from Mon esp with that nap, but look where it is now, very diff to fathom out.

[l0ngterm] 09/1/2018 20:52

NJB: I would assume certain tasks are standard duration, but with the trials low volume of participants and safety record would your colleague expect a quicker turnaround?

[opodio] 09/1/2018 20:28

obiterdicta9 Jan '18 - 16:59 - 9182 of 9201
0 2 1
By fall into place do you mean?:

1. Successful phase 3 - £5 minimum
2. FDA approval - £10 plus
2. Followed by licensing deal or takeover - £20 plus.

OD


love it

[njb67] 09/1/2018 20:21

Spoke to a colleague about clinical trial timelines today. In his experience it takes on average one to two weeks to lock the database after the last set of patient data is collected. How long depends on how quickly the sites respond to data queries on the last few patients.

It then takes on average a few months to conduct the analyses and complete the clinical trial report. So back end of Q1 would seem to be a more likely scenario for the phase three readout than the next few weeks.

Hope useful.

[happyman7] 09/1/2018 19:51

thanks for the video link alphatim, the big bad black wolf was a bit corny and on a personal note, Silvy could do with a a bit of a make over, at least teeth whitening, still she must be a a telented scientist.

[njb67] 09/1/2018 19:37

IIRC ADVFN classifies buys and sells according to whether the trade price is closer to the bid or offer at the time of the trade. This generally works but will misclassify trades if a purchase is made below the mid price or a sale above it. It may explain why share price has fallen but it looks like buys exceed sells.

Personally would not read much into today’s price movements. The fundamentals and investment case for IMM did not change today. That is what to focus on.

[aussieb3] 09/1/2018 19:30

Well price must be controlled other wise it would gone up last 2 day more buys then sells and gone down

[ytsa2] 09/1/2018 19:24

Are orders, even v large ones not filled electronically nowadays. How do the MMs control the price. How many are there for AIM shares generally. Not much knowledge on AIM shares and MMs

[alphatim] 09/1/2018 19:13

hxxps://www.youtube.com/watch?v=ZGRAgfLpcsk
"it (Lupuzor) works" Sylviane Muller, inventor of Lupuzor.
Not exactly the kind of claim a world authority on a subject makes lightly given that her scientific reputation and 30+ years of work is at stake. Last patient out this time next week. No side-effects reported throughout the study or in any previous trial. GLA especially sufferers.

[aussieb3] 09/1/2018 18:55

More buys yesterday as well. pure market manipulation at its best. Just filling them big buys . It should be around the 200 p at minimum with news not that far away

[babanki] 09/1/2018 18:46

Exploratory it wasn't profit taking because there were more buys than sells: 1,029,536 buys against 840,653 sells.

[hamhamham1] 09/1/2018 18:18

Yes, well I guess all are entitled their opinions.
I think obiterdicta was spot on for realistic figures in his earlier post.
I for one will be over the moon with even the lowest of those figures, but if results are good I will enjoy the journey.